Bionano Genomics to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast on November 3, 2022
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, November 3, 2022 at 4:30 p.m. Eastern Time to report financial results for the third quarter 2022 and to highlight recent corporate progress.
| Conference Call & Webcast Details | |
| Date: | Thursday, November 3, 2022 |
| Time: | 4:30 p.m. Eastern Time |
| Live Call: | Toll Free: 1-877-502-9276 Toll/International: 1-720-543-0302 |
| Live Webcast: | https://edge.media-server.com/mmc/p/cz29oo8z |
A replay of the conference call and webcast will be archived on Bionano’s investor relations website at https://ir.bionanogenomics.com/ for at least 30 days.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.
For more information, visit www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com
